OYST Stock Overview
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Oyster Point Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.17 |
| 52 Week High | US$16.61 |
| 52 Week Low | US$3.46 |
| Beta | 1.32 |
| 1 Month Change | 0.54% |
| 3 Month Change | 63.30% |
| 1 Year Change | -29.75% |
| 3 Year Change | -58.38% |
| 5 Year Change | n/a |
| Change since IPO | -40.52% |
Recent News & Updates
Recent updates
Is Oyster Point Pharma (NASDAQ:OYST) Using Debt In A Risky Way?
Nov 08
Oyster Point's nasal spray to be covered by largest Medicare pharmacy benefit manager
Aug 17Oyster Point Pharma, Inc. (NASDAQ:OYST) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 14Oyster Point stock rises 11% after H.C. Wainwright begins coverage with Buy rating
Jul 18Oyster Therapeutics: State Of Business Is Confounding
Jun 30Is Oyster Point Pharma (NASDAQ:OYST) Using Debt In A Risky Way?
Dec 24Oyster Point Pharma (NASDAQ:OYST) Is In A Good Position To Deliver On Growth Plans
Oct 15Oyster Point Pharma starts enrollment in mid-stage Neurotrophic Keratopathy study
Jun 21Here's Why We're Not Too Worried About Oyster Point Pharma's (NASDAQ:OYST) Cash Burn Situation
May 10Need To Know: Oyster Point Pharma, Inc. (NASDAQ:OYST) Insiders Have Been Buying Shares
Feb 09
Oyster Point Pharma files US application for its lead program in dry eye disease
Dec 18Companies Like Oyster Point Pharma (NASDAQ:OYST) Are In A Position To Invest In Growth
Dec 18Oyster Point Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Shareholder Returns
| OYST | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.2% | 0.7% |
| 1Y | -29.7% | -7.0% | 23.0% |
Return vs Industry: OYST underperformed the US Biotechs industry which returned -5.6% over the past year.
Return vs Market: OYST underperformed the US Market which returned -21.7% over the past year.
Price Volatility
| OYST volatility | |
|---|---|
| OYST Average Weekly Movement | 12.4% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OYST's share price has been volatile over the past 3 months.
Volatility Over Time: OYST's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 303 | Jeff Nau | www.oysterpointrx.com |
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company’s product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy.
Oyster Point Pharma, Inc. Fundamentals Summary
| OYST fundamental statistics | |
|---|---|
| Market cap | US$303.21m |
| Earnings (TTM) | -US$176.64m |
| Revenue (TTM) | US$19.58m |
15.5x
P/S Ratio-1.7x
P/E RatioIs OYST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OYST income statement (TTM) | |
|---|---|
| Revenue | US$19.58m |
| Cost of Revenue | US$4.52m |
| Gross Profit | US$15.07m |
| Other Expenses | US$191.71m |
| Earnings | -US$176.64m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.51 |
| Gross Margin | 76.93% |
| Net Profit Margin | -901.99% |
| Debt/Equity Ratio | -415.4% |
How did OYST perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/01/04 03:01 |
| End of Day Share Price | 2022/12/30 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oyster Point Pharma, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniil Gataulin | Chardan Capital Markets, LLC |
| Matthew Caufield | H.C. Wainwright & Co. |
| Anupam Rama | J.P. Morgan |